Evercore

Central Bankers Around The Globle Scramble To Defend Markets: BOE Pledges $345BN; ECB, Others Promise Liquidity

There was a reason why we warned readers two days ago that "The World's Central Bankers Are Gathering At The BIS' Basel Tower Ahead Of The Brexit Result": simply enough, it was to facilitate an immediate response when a worst-cased Brexit vote hit. And that is precisely what has happened today in the aftermath of the historic British decision to exit the EU.  It started, as one would expect, with Mark Carney who said the Bank of England is ready to pump billions of pounds into the financial system as he stands at the front line of Britain’s defense against a Brexit-provoked market crisis.

Caterpillar Retail Sales Decline For Unprecedented 42nd Consecutive Month

Here is the chart that confirms that any light at the end of the industrial and heavy manufacturing tunnel is most likely just one of the few trains still running: there are now 42 consecutive month of CAT retail sales declines. This has never happened in the company's history.

"We Are Unsure Whether To Wear A Helmet Or A Diaper" - Merger Arb Funds Crushed

While company officers - who have given up on major stock upside as a result of busted M&A - and investment bankers are lamenting the bursting of the M&A bubble, some of the biggest losers are on the buyside, where merger arbs have seen billions in paper profits turn into billions in paper losses in moments upon the announcement of deal termination. Indeed, broken deals have whipsawed hedge funds that focus on merger arbitrage. As the NYT poetically puts it, according to one "arb" the current mood of the industry: "Every day is like showing up unsure of whether to wear a helmet or a diaper."

Mega M&A Is Back: Abbott Buys St. Jude Medical For $25 Billion, 37% Premium

The great megadeal M&A drought of 2016 just came to an end when moments ago Abbott announced it would acquire St. Jude Medical for $25 billion, roughly a 37% premium to St. Jude's Wednesday closing price. According to the press release, under the agreement, St. Jude Medical shareholders will receive $46.75 in cash and 0.8708 shares of Abbott common stock, representing total consideration of approximately $85 per share. At an Abbott stock price of $43.93(2), this represents a total transaction equity value of $25 billion.

A "Massive" New Headache For Banks Has Emerged

It's not just the shale drillers who are in danger as they see their liquidity evaporate. As the WSJ writes today, and as covered here since January, it is the lenders themselves whose unfunded revolver exposure may suddenly become funded and expose them to even greater risks from the energy sector should oil not rebound far more forcefully and put US oil and gas companies back in the black. How big is the exposure? Very big: $147 billion.

Is The Allergan-Pfizer Deal Over? What Wall Street Thinks

Yesterday's stunning announcement by the US Treasury, which released a report titled  "Treasury Announces Additional Action to Curb Inversions, Address Earnings Stripping", and which was clearly aimed at ending not only all tax inversions, but the biggest pharma M&A deal in history, Pfizer's tax-inverting takeover of Allergan (pardon Actavis) hit AGN like a ton of bricks, sending the stock crashing 20%.  But is the deal over? Here are some Wall Street opinions.

Q1 Slams Hedgies 'Most Popular Trade' - Momo Crashes Most Since 2009

In mid-February, we warned of the looming carnage for equity market-neutral funds, and sure enough, as Bloomberg reports, one of the most popular (and successful) hedge fund trades - playing the difference between high- and low-momentum stocks - crashed by the most since 2009 in Q1. After 6 years of almost unstoppable gains, equity market-neutral funds suffered their biggest losses since 2012 - comparable to the 2007 quant crisis devastation - as weak momo stocks massively outpeformed crushing the hedgies' models.

Fed's Flip-flopping Causes Technicians To Lose The Plot

" I would only add that even if one were Bullish at this point, which is perfectly reasonable (not my call, but reasonable), that with almost 94% of stocks above their 50 day ma while volatility, currencies and inflation expectations have surged into levels which coincided with prior inflection points across the risk spectrum, a consolidative pause and pullback remains on the table. 2077-2086 stop."

Crushed By The Record Oil Squeeze, This Is How Energy Bears Are Shorting Crude Now

The result of the recent mega short squeeze in oil, has been a significant revulsion to shorting oil directly or indirectly, either by way of the underlying commodity or energy stocks, many of which have soared in tandem. And yet the shorts remain, and continue to press their bets on the troubled energy sector. However, instead of directly shorting crude and various first-derivative oil and gas companies, short sellers - burned by the recent squeeze - have changed their strategy and shifted their sights to secondary exposure, namely those regional banks that do business with the industry.

Sell In March And Go Away? There's Something About April During Election Years

"We transition from the best 6 month stretch for the S&P since 1950 into the worst 6 month stretch which commences in May. Moreover, while April has been the best month for the Dow over the past 65 years (+2.0%) during Presidential Election Year's April falls from a 1 seed to an 11 seed with an average loss of .9% according to the Stock Trader's Almanac"

One Of The Most Accurate Forecasters Of 2016: "S&P Is The Most Overbought Since 2009: Sell!"

"The US market is extremely overbought, and from a cyclical standpoint the SPX is trading in the time window of our late March/early April top projection. In this context, we see the US market vulnerable for a significant reversal this week, which we would see as the beginning of a tactical top building process and subsequent correction into deeper/later Q2."

Valeant Throws Its Former CFO Under The Bus; Accuses Him Of Cooking The Books After Coming Over From Goldman Sachs

Back in October, we tried to "tie the Valeant roll-up together by presenting The Goldman "Missing Link" in which we showed that Howard Schiller, Valeant's CFO from December 2011 to June 2015, previously ran Goldman Sachs’ health-care practice until 2009, when he became the chief operating officer of Goldman’s investment bank. The next year, the bank advised Valeant on its breakout purchase of Biovail Corp. Today, as part of its stunning announcement earlier today, the company - in looking for easy scapegoats - also threw its former CFO under the bus and accused him of cooking the books.

All The Latest Chinese News In Just 7 Bullets

(1) Incoming Jan-Feb data still choppy; (2) Our Synthetic Growth Index (SGI) likely down for Jan and Feb, after up Sep-Dec; (3) As China slows, no problem is too small for a new policy fix; (4) Housing: too many vacant units, in the wrong places, wrong size and wrong price.; (5) SOEs:  excess capacity, old, inefficient in most key China industries. (6) Equities:  recent rally welcome but markets still broken just when more equity financing is needed. (7) NPLs: from past bad decisions, rising sharply.